Innovations In Clinical Neuroscience

SEP-OCT 2014

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/425963

Contents of this Issue

Navigation

Page 4 of 201

E ditor's Message ........................................3 A nnotated Table of Contents ...................6 Editorial Advisory Board ........................10 O RIGINAL RESEARCH P rospective Assessment of Suicidal Ideation and Behavior: An Internet Survey of Pharmaceutical Sponsor P ractices ...................................................14 by ISCTM Suicidal Ideation and Behavior A ssessment Workgroup: Phillip B. Chappell, M D; Atul R. Mahableshwarkar, MD; Larry D. Alphs, MD, PhD; Mark E. Bangs, MD; Adam Butler, BA; Sarah J. Dubrava, MS; John H. Greist, MD; William R. Lenderking, PhD; James C. Mundt, PhD; and Michelle Stewart, PhD Predictive Value of Baseline Electronic Columbia–Suicide Severity Rating Scale (eC–SSRS) Assessments for Identifying Risk of Prospective Reports of Suicidal Behavior During Research Participation ............................................23 by John H. Greist, MD; James C. Mundt, PhD; Chad J. Gwaltney, PhD; James W. Jefferson, MD; and Kelly Posner, PhD Comparative Validation of the S-STS, the ISST-Plus, and the C–SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality Categories ....................32 by David V. Sheehan, MD, MBA; Larry D. Alphs, MD, PhD; Lian Mao, PhD; Qin Li; Roberta S. May, MA; Emily H. Bruer, M.ed; Cheryl B. McCullumsmith, MD, PhD; Christopher R. Gray, BS; Xiaohua Li; and David J. Williamson, PhD Simple Measures of Hopelessness and Impulsivity are Associated with Acute Suicidal Ideation and Attempts in Patients in Psychiatric Crisis.................................47 by Cheryl B. McCullumsmith, MD, PhD; David J. Williamson, PhD; Roberta S. May, MA; Emily H. Bruer, M.ed; David V. Sheehan, MD, MBA; and Larry D. Alphs, MD, PhD CRITICAL REVIEWS Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical Review ...............54 by David V. Sheehan, MD, MBA; Jennifer M. Giddens; and Kathy Harnett Sheehan, PhD The Columbia–Suicide Severity Rating Scale (C–SSRS): Has the "Gold Standard" Become a Liability? .................................66 by Jennifer M. Giddens; Kathy Harnett Sheehan, PhD; and David V. Sheehan, MD, MBA A re Suicide Terrorists Suicidal? A Critical Assessment of the Evidence ...................81 b y Ivan Sascha Sheehan, PhD REPORTS S tatus Update on the Sheehan-Suicidality Tracking Scale (S-STS) 2014 ..................93 b y David V. Sheehan, MD, MBA; Jennifer M. Giddens; and Ivan Sascha Sheehan, PhD L inguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STS) .........................141 by Darlene M. Amado, BA; Darlene A. Beamon, BSE, MA; and David V. Sheehan, MD, MBA CASE STUDIES The Complexity of Assessing Overall Severity of Suicidality: A Case Study ..164 by Jennifer M. Giddens and David V. Sheehan, MD, MBA Do the Five Combinations of Suicidal Ideation in the FDA 2012 Draft Guidance Document and the C–SSRS Adequately Cover All Suicidal Ideation Combinations in Practice? A Case Study .....................172 by Jennifer M. Giddens and David V. Sheehan, MD, MBA Is a Count of Suicidal Ideation and Behavior Events Useful in Assessing Global Severity of Suicidality? A Case Study .......................................................179 by Jennifer M. Giddens and David V. Sheehan, MD, MBA Is There Value in Asking the Question "Do you think you would be better off dead?" in Assessing Suicidality? A Case Study .......................................................182 by Jennifer M. Giddens and David V. Sheehan, MD, MBA How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case Study..............................................191 by Jennifer M. Giddens and David V. Sheehan, MD, MBA RESEARCH TO PRACTICE Assessment of Suicidal Behavior in the Emergency Department for Clinical Trial Results ....................................................194 by Steven D. Targum, MD; Frank Friedman, MD; and Manuel N. Pacheco, MD, FAPM, DFAPA Information for Authors .........................55 Business Staff E DITOR Amir H. Kalali, MD V ice President, Global Therapeutic Group Leader CNS, Quintiles Inc.; Professor of Psychiatry, University of C alifornia, San Diego, California PRESIDENT/GROUP PUBLISHER R obert L. Dougherty Matrix Medical Communications W est Chester, Pennsylvania P ARTNER P atrick D. Scullin Matrix Medical Communications W est Chester Pennsylvania V ICE PRESIDENT, BUSINESS DEVELOPMENT Joseph J. Morris Matrix Medical Communications W est Chester, Pennsylvania V ICE PRESIDENT, EXECUTIVE EDITOR Elizabeth A. Klumpp M atrix Medical Communications West Chester, Pennsylvania A SSOCIATE EDITOR Kimberly B. Chesky M atrix Medical Communications West Chester, Pennsylvania ASSISTANT EDITOR Angela M. Saba Matrix Medical Communications West Chester, Pennsylvania EDITORIAL CORRESPONDENCE should be directed to Executive Editor, Innovations in Clinical Neuroscience, Matrix Medical Communications, 1595 Paoli Pike, Suite 103, West Chester, PA 19380. Toll-free: (866) 325-9907; Phone: (484) 266-0702; Fax: (484) 266-0726; E-mail: eklumpp@matrixmedcom.com INDEXING— PubMed Central, PsycINFO, CINAHL ® Plus with Full Text, Scopus, and Embase ADVERTISING QUERIES For web advertising (website and enewsletters): Brett Baxter, Director, Business Development, UBM Medica; E-mail: brett.baxter@ubm.com; Phone: (347) 327-1316 For display advertising (e-journal and print): Robert Dougherty, President/Group Publisher, Matrix Medical Communications; E-mail: rdougherty@matrixmed- com.com; Phone: (484) 266-0702 Copyright © 2014 Matrix Medical Communications. All rights reserved. Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Matrix Medical Communications, the editorial staff, or any member of the editorial advisory board. Matrix Medical Communications is not responsible for accuracy of dosages given in the articles printed herein. The appearance of advertisements in this journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Matrix Medical Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements. Reprints are available. Contact Matrix Medical Communications for information. Innovations in Clinical Neuroscience, ISSN 2158-8333 (Print) and ISSN 2158-8341(Online), is published 12 times yearly by Matrix Medical Communications via www.innovationscns.com. To receive an e-mail when a new issue is available, please visit the website or e-mail eklumpp@matrixmedcom.com. Formerly published as Psychiatry 2010 and indexed as Psychiatry (Edgmont). Hard copy subscriptions are available for purchase. Visit www.innovationscns.com for information. In This Issue Vo l . 1 1 , N o . 9 – 1 0 , S e p t e m b e r – O c t o b e r 2 0 1 4 [ V O L U M E 1 1 , N U M B E R 9 – 1 0 , S E P T E M B E R – O C T O B E R 2 0 1 4 ] Innovations in CLINICAL NEUROSCIENCE 5 Assessment of Suicidal Ideation and Behavior— A Compendium of Current Research and Practice

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - SEP-OCT 2014